DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins

Phase 1

Completed

Conditions: Atherosclerosis

Interventions: Biological: BMS-962476
Biological: Placebo matching with BMS-962476

First Posted Date: 2012-04-30

Last Posted Date: 2013-09-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 66

Registration Number: NCT01587365

Locations: 🇺🇸
Metabolic And Atherosclerosis Research Center/ Medpace Clinical Pharmacology, Cincinnati, Ohio, United States

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Phase 2

Completed

Conditions: Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction

Interventions: Other: Best Supportive care (BSC)
Biological: Ipilimumab

First Posted Date: 2012-04-26

Last Posted Date: 2016-05-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 143

Registration Number: NCT01585987

Locations: 🇺🇸
Mount Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸
Nyu Clinical Cancer Center, New York, New York, United States
🇺🇸
The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: SAR302503
Drug: omeprazol
Drug: metoprolol
Drug: midazolam

First Posted Date: 2012-04-26

Last Posted Date: 2025-03-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT01585623

Locations: 🇺🇸
Investigational Site Number 840004, Augusta, Georgia, United States
🇺🇸
Investigational Site Number 840002, Philadelphia, Pennsylvania, United States
🇺🇸
Investigational Site Number 840001, Detroit, Michigan, United States

Korean Post-marketing Surveillance for Orencia®

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: No Intervention (subjects were previously treated with Orencia®)

First Posted Date: 2012-04-23

Last Posted Date: 2016-05-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 701

Registration Number: NCT01583244

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

Phase 3

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: Asunaprevir (ASV)
Drug: Daclatasvir (DCV)
Drug: Pegylated-interferon alfa 2a (PegIFN)
Drug: Ribavirin (RBV)

First Posted Date: 2012-04-20

Last Posted Date: 2015-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 748

Registration Number: NCT01581203

Locations: 🇺🇸
The Health Care Authority For Baptist Health, Montgomery, Alabama, United States
🇺🇸
Scpmg/ Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
University Of Colorado Denver And Hospital, Aurora, Colorado, United States

and more 24 locations

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Phase 3

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: Asunaprevir
Drug: Daclatasvir
Drug: Peg-interferon Alfa-2a
Drug: Ribavirin

First Posted Date: 2012-04-09

Last Posted Date: 2015-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 398

Registration Number: NCT01573351

Locations: 🇺🇸
University Of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Gastro One, Germantown, Tennessee, United States
🇨🇳
Local Institution, Taipei, Taiwan

and more 18 locations

Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Brivanib

First Posted Date: 2012-02-28

Last Posted Date: 2014-07-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 17

Registration Number: NCT01540461

Locations: 🇨🇳
Local Institution, Nanjing, Jiangsu, China

Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Completed

Conditions: Hepatitis C

Interventions: Drug: Peginterferon Lambda-1a (BMS-914143)

First Posted Date: 2012-02-03

Last Posted Date: 2015-03-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 218

Registration Number: NCT01525810

Locations: 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸
Gastrointestinal Specialists Of Georgia, Marietta, Georgia, United States

and more 16 locations

Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BMS-754807 (IGR-IR/IR Inhibitor)
Drug: Metformin

First Posted Date: 2012-02-03

Last Posted Date: 2012-06-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 26

Registration Number: NCT01525823

Locations: 🇦🇺
Local Institution, Melbourne, Victoria, Australia

Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients

Phase 1

Withdrawn

Conditions: Chronic Hepatitis C

Interventions: Drug: BMS-929075
Drug: Placebo matching BMS-929075

First Posted Date: 2012-02-02

Last Posted Date: 2013-06-21

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT01525212

Locations: 🇦🇺
Local Institution, Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy